These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 36901951)
21. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis. Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711 [TBL] [Abstract][Full Text] [Related]
22. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486 [TBL] [Abstract][Full Text] [Related]
24. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma. Kim CG; Kim M; Hwang J; Kim ST; Jung M; Kim KH; Kim KH; Chang JS; Koom WS; Roh MR; Chung KY; Kim TM; Kim SK; Lee J; Shin SJ J Am Acad Dermatol; 2022 Nov; 87(5):989-996. PubMed ID: 36068115 [TBL] [Abstract][Full Text] [Related]
26. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907 [TBL] [Abstract][Full Text] [Related]
27. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748 [TBL] [Abstract][Full Text] [Related]
28. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351 [TBL] [Abstract][Full Text] [Related]
29. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Roskoski R Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260 [TBL] [Abstract][Full Text] [Related]
30. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667 [TBL] [Abstract][Full Text] [Related]
31. Trametinib (GSK1120212) in the treatment of melanoma. Salama AK; Kim KB Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625 [TBL] [Abstract][Full Text] [Related]